Gut microbiome modulates efficacy of immune checkpoint inhibitors

Area of Science:

• Oncology
• Immunology
• Microbiome Research

Background:

• Immune checkpoint inhibitors (ICIs) represent a significant advancement in cancer therapy.
• A substantial proportion of patients exhibit resistance to ICIs, limiting their clinical utility.
• Understanding resistance mechanisms is critical for enhancing ICI efficacy.

Purpose of the Study:

• To review the current understanding of the gut microbiome's influence on ICI therapy.
• To explore the modulatory functions of the gut microbiome in cancer immunotherapy.
• To investigate potential antitumor mechanisms of gut commensals in conjunction with ICIs.

Main Methods:

• Literature review of studies investigating the gut microbiome and ICI therapy.
• Analysis of preclinical xenograft models and clinical patient data.
• Synthesis of findings on microbiome composition and immunotherapy response.

Main Results:

• Gut microbiome composition significantly impacts patient response to ICIs.
• Specific gut bacteria have been identified as crucial regulators of immunotherapy efficacy.
• Evidence from both animal models and human studies supports the microbiome's role.

Conclusions:

• The gut microbiome is a critical factor influencing ICI treatment outcomes.
• Gut microbiome manipulation presents a viable strategy to improve response rates to ICIs.
• The microbiome may serve as an important predictive biomarker for ICI therapy.